Pharmacogenomic Information

DrugTherapeutic Area*
Labeling Sections
MipomersenEndocrinologyLDLRLDLR mutation heterozygotes and homozygotes
(heterozygous and homozygous familial hypercholesterolemia)
Boxed Warning, Indications and Usage, Warnings and Precautions,
Adverse Reactions, Use in Specific Populations, Clinical Studies


* Therapeutic areas do not necessarily reflect the CDER review division.

† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.


back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 04/20/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English